Expired CME Article

Clostridium difficile: An Update for the Primary Care Clinician

Authors: Alan R. Salkind, MD

Abstract

Clostridium difficile infection (CDI) is an important cause of intestinal disease, primarily affecting hospitalized patients exposed to antibiotics. Infection has been associated with prolonged hospital stays and excess healthcare expenditures. Recent changes in the epidemiology, pathogenesis, and treatment of CDI have occurred, leading to renewed scrutiny of this pathogen. Increases in its incidence and severity have been documented, possibly due to the emergence of a hypervirulent strain that produces high levels of toxins. Community-acquired cases in individuals without traditional risk factors have been reported. Furthermore, oral metronidazole may not be as effective as oral vancomycin for patients with severe CDI. New therapies are being investigated for patients with recurrent disease. This review highlights the new developments in the epidemiology, pathogenesis, and management of CDI, serving as an up-to-date resource for primary care clinicians.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008;46(suppl 1):S4–S11.
 
2. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992–998.
 
3. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. [Review.] Clin Infect Dis 2008;46(suppl 1):S12–S18.
 
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis 2007;13:1417–1419.
 
5. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
 
6. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219–1227.
 
7. Elixhauser A, Jhung M. Clostridium difficile-associated disease in U.S. Hospitals, 1993–2005. Healthcare cost and utilization project. Statistical brief #50 2008. Search: Clostridium difficile. Available at: www.hcup-us.ahrq.gov. Accessed January 5, 2009.
 
8. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466–472.
 
9. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
 
10. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults.Int J Antimicrob Agents 2009;33(suppl 1):S42–S45.
 
11. Surveillance for community-associated Clostridium difficile–Connecticut, 2006. Mor Mortal Wkly Rep 2008;57:340–343.
 
12. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127–133.
 
13. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;179:767–772.
 
14. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk—four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201–1205.
 
15. Bartlett JG, Onderdonk AB, Cisneros RL, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701–705.
 
16. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009;458:1176–1179.
 
17. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain ofClostridium difficile. N Engl J Med 2005;353:2433–2441.
 
18. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficileassociated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079–1084.
 
19. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037–1042.
 
20. Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002;34:1585–1592.
 
21. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review [review]. Clin Infect Dis 1993;17:109–113.
 
22. Pierce PF Jr, Wilson R, Silva J Jr, et al. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infec Dis 1982;145:269–274.
 
23. Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009;151:176–179.
 
24. Gerding D, Muto C, Owens RJ. Treatment of Clostridium difficile infection. Clin Infect Dis2008;46(suppl 1):S32–S42.
 
25. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009;47:373–378.
 
26. FDA approves rapid DNA test to detect Clostridium difficile infection. Search: rapid DNA test to detect Clostridium difficile infection. Available at: www.medscape.com. Accessed January 5, 2010.
 
27. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549–557.
 
28. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005;54:101–111.
 
29. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.
 
30. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008;46:1493–1498.
 
31. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173:167–170.
 
32. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54:905–906.
 
33. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007;35:131–137.
 
34. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640–645.
 
35. Borody TJ. “Flora power”—fecal bacteria cure chronic C. difficile diarrhea. Am J Gastroenterol2000;95:3028–3029.
 
36. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580–585.
 
37. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficilecolitis. Clin Infect Dis 2006;43:421–427.
 
38. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficileinfection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41–e46. Available at: http://www.journals.uchicago.edu/toc/cid/current. Accessed January 4, 2009.
 
39. Dryden B, Mohammed R, Chasen-Taber S, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Costridium difficile-associated diarrhoea [abstract 0464]. Presented at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 2008.
 
40. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother2004;54:168–172.
 
41. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. Q J Med 2004;97:423–429.